Literature DB >> 18989752

Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase.

Carlos J Alméciga-Díaz1, Maria A Rueda-Paramo, Angela J Espejo, Olga Y Echeverri, Adriana Montaño, Shunji Tomatsu, Luis A Barrera.   

Abstract

Morquio A is an autosomal recessive disease caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), leading to the lysosomal accumulation of keratan-sulfate and chondroitin-6-sulfate. We evaluated in HEK293 cells the effect of the cytomegalovirus immediate early enhancer/promoter (CMV) or the elongation factor 1alpha (EF1alpha) promoters, and the coexpression with the sulfatase modifying factor 1 (SUMF1) on GALNS activity. Four days postransfection GALNS activity in transfected cells with CMV-pIRES-GALNS reached a plateau, whereas in cells transfected with EF1alpha-pIRES-GALNS continued to increase until day 8. Co-transfection with pCXN-SUMF1 showed an increment up to 2.6-fold in GALNS activity. Finally, computational analysis of transcription factor binding-sites and CpG islands showed that EF1alpha promoter has long CpG islands and high-density binding-sites for Sp1 compared to CMV. These results show the advantage of the SUMF1 coexpression on GALNS activity and indicate a considerable effect on the expression stability using EF1alpha promoter compared to CMV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989752     DOI: 10.1007/s11033-008-9392-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

Review 1.  The RNA polymerase II core promoter: a key component in the regulation of gene expression.

Authors:  Jennifer E F Butler; James T Kadonaga
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

2.  Modulation of plasmid DNA methylation and expression in zebrafish embryos.

Authors:  P Collas
Journal:  Nucleic Acids Res       Date:  1998-10-01       Impact factor: 16.971

3.  Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.

Authors:  S C Jung; I P Han; A Limaye; R Xu; M P Gelderman; P Zerfas; K Tirumalai; G J Murray; M J During; R O Brady; P Qasba
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

5.  Coexpression of formylglycine-generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy.

Authors:  Yukiko Takakusaki; Sanae Hisayasu; Yukihiko Hirai; Takashi Shimada
Journal:  Hum Gene Ther       Date:  2005-08       Impact factor: 5.695

6.  Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle.

Authors:  Alan R Brooks; Richard N Harkins; Peiyin Wang; Hu Sheng Qian; Pengxuan Liu; Gabor M Rubanyi
Journal:  J Gene Med       Date:  2004-04       Impact factor: 4.565

7.  Sp1 elements protect a CpG island from de novo methylation.

Authors:  M Brandeis; D Frank; I Keshet; Z Siegfried; M Mendelsohn; A Nemes; V Temper; A Razin; H Cedar
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

8.  Enzyme replacement therapy in a murine model of Morquio A syndrome.

Authors:  Shunji Tomatsu; Adriana M Montaño; Amiko Ohashi; Monica A Gutierrez; Hirotaka Oikawa; Toshihiro Oguma; Vu Chi Dung; Tatsuo Nishioka; Tadao Orii; William S Sly
Journal:  Hum Mol Genet       Date:  2007-12-03       Impact factor: 6.150

9.  The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.

Authors:  Maria Pia Cosma; Stefano Pepe; Ida Annunziata; Robert F Newbold; Markus Grompe; Giancarlo Parenti; Andrea Ballabio
Journal:  Cell       Date:  2003-05-16       Impact factor: 41.582

Review 10.  Mammalian RNA polymerase II core promoters: insights from genome-wide studies.

Authors:  Albin Sandelin; Piero Carninci; Boris Lenhard; Jasmina Ponjavic; Yoshihide Hayashizaki; David A Hume
Journal:  Nat Rev Genet       Date:  2007-05-08       Impact factor: 53.242

View more
  15 in total

Review 1.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

Review 2.  Morquio A syndrome: diagnosis and current and future therapies.

Authors:  Shunji Tomatsu; Eriko Yasuda; Pravin Patel; Kristen Ruhnke; Tsutomu Shimada; William G Mackenzie; Robert Mason; Mihir M Thacker; Mary Theroux; Adriana M Montaño; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; William S Sly; Daniel Rowan; Yasuyuki Suzuki; Tado Orii
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

3.  Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA.

Authors:  Andrés Felipe Leal; Carlos Javier Alméciga-Díaz
Journal:  Gene Ther       Date:  2022-05-18       Impact factor: 5.250

4.  Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A.

Authors:  Sergio Olarte-Avellaneda; Alexander Rodríguez-López; Carlos Javier Alméciga-Díaz; Luis Alejandro Barrera
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

5.  Current and emerging treatments and surgical interventions for Morquio A syndrome: a review.

Authors:  Shunji Tomatsu; William G Mackenzie; Mary C Theroux; Robert W Mason; Mihir M Thacker; Thomas H Shaffer; Adriana M Montaño; Daniel Rowan; William Sly; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; Eriko Yasuda; Kristen Ruhnke; Yasuyuki Suzuki; Tadao Orii
Journal:  Res Rep Endocr Disord       Date:  2012-12

6.  Current therapies for Morquio A syndrome and their clinical outcomes.

Authors:  Kazuki Sawamoto; Yasuyuki Suzuki; William G Mackenzie; Mary C Theroux; Christian Pizarro; Hiromasa Yabe; Kenji E Orii; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2016-07-28       Impact factor: 0.694

7.  Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).

Authors:  Shunji Tomatsu; Carlos J Alméciga-Díaz; Hector Barbosa; Adriana M Montaño; Luis A Barrera; Tsutomu Shimada; Eriko Yasuda; William G Mackenzie; Robert W Mason; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii
Journal:  Expert Opin Orphan Drugs       Date:  2013-10-01       Impact factor: 0.694

8.  In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.

Authors:  Shuo Shi; Min Zhang; Rui Guo; Ying Miao; Jiajia Hu; Yun Xi; Biao Li
Journal:  PLoS One       Date:  2015-01-26       Impact factor: 3.240

9.  Generation of a genome scale lentiviral vector library for EF1α promoter-driven expression of human ORFs and identification of human genes affecting viral titer.

Authors:  Dubravka Škalamera; Mareike Dahmer; Amy S Purdon; Benjamin M Wilson; Max V Ranall; Antje Blumenthal; Brian Gabrielli; Thomas J Gonda
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

10.  Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris.

Authors:  Alexander Rodríguez-López; Carlos J Alméciga-Díaz; Jhonnathan Sánchez; Jefferson Moreno; Laura Beltran; Dennis Díaz; Andrea Pardo; Aura María Ramírez; Angela J Espejo-Mojica; Luisa Pimentel; Luis A Barrera
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.